About Coherus BioSciences
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CHRS
- Previous Close: $22.50
- 50 Day Moving Average: $26.25
- 200 Day Moving Average: $28.09
- 52-Week Range: $13.10 - $31.98
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.06
- P/E Growth: 0.00
- Market Cap: $1.00B
- Outstanding Shares: 43,652,000
- Beta: 4.82
- Net Margins: -52.04%
- Return on Assets: -47.08%
Companies Related to Coherus BioSciences:
- Debt-to-Equity Ratio: 3.15%
- Current Ratio: 3.04%
- Quick Ratio: 3.04%
What is Coherus BioSciences' stock symbol?
Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."
Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?
7 equities research analysts have issued 1-year price objectives for Coherus BioSciences' stock. Their predictions range from $35.00 to $46.00. On average, they anticipate Coherus BioSciences' share price to reach $39.71 in the next twelve months.
When will Coherus BioSciences announce their earnings?
Coherus BioSciences is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Coherus BioSciences stock?
Coherus BioSciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (2.18%), Orbimed Advisors LLC (1.95%), Highland Capital Management LP (0.82%), Brown Advisory Inc. (0.77%) and JHL Capital Group LLC (0.57%). Company insiders that own Coherus BioSciences stock include Alan C Herman, August J Troendle, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler.
Who sold Coherus BioSciences stock? Who is selling Coherus BioSciences stock?
Coherus BioSciences' stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC, Highland Capital Management LP and Commerzbank Aktiengesellschaft FI. Company insiders that have sold Coherus BioSciences stock in the last year include Alan C Herman, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler.
Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?
Coherus BioSciences' stock was acquired by a variety of institutional investors in the last quarter, including JHL Capital Group LLC, Orbimed Advisors LLC, State Street Corp, Two Sigma Investments LP, Thrivent Financial for Lutherans, FMR LLC, Russell Investments Group Ltd. and Marshall Wace LLP.
How do I buy Coherus BioSciences stock?
Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Coherus BioSciences stock cost?
One share of Coherus BioSciences stock can currently be purchased for approximately $22.70.